It is very uncertain whether extended‐field chemoradiotherapy changes acute adverse events compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes late adverse events compared with pelvic chemoradiotherapy (very low certainty).
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
Extended prophylaxis showed no clear difference in recurrent VTEc compared with placebo (moderate certainty).
Extended prophylaxis showed no clear difference in major bleedinge compared with placebo (low certainty).
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).
Extended prophylaxis showed no clear difference in strokei compared with placebo (low certainty).
Extended prophylaxis showed no clear difference in myocardial infarction compared with placebo (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission at 6 months among those whose HIV diagnostic… compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes HIV Transmission or Death at 6 months among those whose HIV… compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infants with Grade 3/4 Severe Adverse Events compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in maternal Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in mothers with any Grade 3/4 Severe Adverse Event compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes mothers with Severe Adverse Events Requiring Treatment Modification compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
The review found no eligible studies for this question.